CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS (LOSS) (UNAUDITED) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
REVENUE
Product sales	$ 19,212	$ 20,979
License and fee income	661	604
Revenue	19,873	21,583
COST OF SALES	12,848	12,974
GROSS PROFIT	7,025	8,609
OPERATING EXPENSES
Selling, general and administrative	5,678	5,901
Amortization of purchased intangibles	861	855
Research and development	280	277
Medical device excise tax	193
Gain on disposal of assets	(4)
Operating expenses	7,008	7,033
EARNINGS FROM OPERATIONS	17	1,576
OTHER INCOME (EXPENSE)
Interest income	27	38
Interest expense	(136)	(164)
Other		1
Other income (expense)	(109)	(125)
EARNINGS (LOSS) BEFORE INCOME TAXES	(92)	1,451
Income tax expense (benefit)	(58)	517
NET EARNINGS (LOSS)	(34)	934
EARNINGS PER SHARE:
Basic (in dollars per share)	$ 0.00	$ 0.03
Diluted (in dollars per share)	$ 0.00	$ 0.03
WEIGHTED AVERAGE SHARES
Basic (in shares)	29,065	33,533
Diluted (in shares)	29,065	33,941
COMPREHENSIVE EARNINGS (LOSS)
Net earnings (loss)	(34)	934
Other comprehensive earnings (loss), net of taxes
Reclassification adjustment for gain included in net earnings (loss)		(1)
Unrealized gains on securities arising during the period		57
Total other comprehensive earnings		56
Total comprehensive earnings (loss)	$ (34)	$ 990